Comparison 18.

Taspoglutide versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 HbA1c (%)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Taspoglutide 10 mg once weekly verus placebo	1	98	Mean Difference (IV, Random, 95% CI)	‐1.0 [‐1.19, ‐0.81]
1.2 Taspoglutide 20 mg once weekly versus placebo	2	163	Mean Difference (IV, Random, 95% CI)	‐0.87 [‐1.16, ‐0.58]
1.3 Taspoglutide 20 mg once every 2 weeks versus placebo	1	98	Mean Difference (IV, Random, 95% CI)	‐0.8 [‐0.99, ‐0.61]
2 HbA1c (%)			Other data	No numeric data
3 HbA1c < 7%	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Taspoglutide 10 mg once weekly versus placebo	1	98	Risk Ratio (M‐H, Random, 95% CI)	4.88 [2.55, 9.33]
3.2 Taspoglutide 20 mg once weekly versus placebo	2	163	Risk Ratio (M‐H, Random, 95% CI)	4.41 [2.70, 7.22]
3.3 Taspoglutide 20 mg once every two weeks versus placebo	1	98	Risk Ratio (M‐H, Random, 95% CI)	3.88 [1.99, 7.56]
4 HbA1c < 7%			Other data	No numeric data
5 Hypoglycaemia	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 Taspoglutide 20/20 mg once weekly versus placebo	1	64	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.07, 15.30]
5.2 Taspoglutide 20/30 mg once weekly versus placebo	1	65	Risk Ratio (M‐H, Random, 95% CI)	2.91 [0.32, 26.53]
5.3 Taspoglutide 20/40 mg once weekly versus placebo	1	64	Risk Ratio (M‐H, Random, 95% CI)	2.0 [0.19, 20.97]
6 Hypoglycaemia			Other data	No numeric data
7 Weight change (kg)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Taspoglutide 10 mg once weekly versus placebo	1	88	Mean Difference (IV, Random, 95% CI)	‐1.3 [‐2.13, ‐0.47]
7.2 Taspoglutide 20 mg once weekly versus placebo	2	153	Mean Difference (IV, Random, 95% CI)	‐1.07 [‐2.93, 0.79]
7.3 Taspoglutide 20 mg once every two weeks versus placebo	1	80	Mean Difference (IV, Random, 95% CI)	‐1.10 [‐1.93, ‐0.27]
8 Weight change			Other data	No numeric data
9 Adverse events			Other data	No numeric data
10 Adverse events			Other data	No numeric data
11 Fasting plasma glucose (mmol/L)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
11.1 Taspoglutide 20/20 mg once weekly versus placebo	1	64	Mean Difference (IV, Random, 95% CI)	‐1.70 [‐2.53, ‐0.87]
11.2 Taspoglutide 20/30 mg once weekly versus placebo	1	65	Mean Difference (IV, Random, 95% CI)	‐1.0 [‐1.83, ‐0.17]
11.3 Taspoglutide 20/40 mg once weekly versus placebo	1	64	Mean Difference (IV, Random, 95% CI)	‐1.6 [‐2.43, ‐0.77]
12 Fasting plasma glucose			Other data	No numeric data
13 Postprandial glucose and insulin			Other data	No numeric data
14 Lipid profiles			Other data	No numeric data
15 Beta‐cell function			Other data	No numeric data
16 Subgroup			Other data	No numeric data
16.1 Participants with HbA1c ≥8%			Other data	No numeric data